Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 27, 2025

Primary Completion Date

September 30, 2026

Study Completion Date

March 30, 2028

Conditions
AIHA - Cold Autoimmune Hemolytic Anemia
Interventions
DRUG

Inaticabtagene Autoleucel Injection

"The dose was incremented according to the 3+3 principle, and the three dose levels A, B and C were given in sequence at one time, which were respectively:~A-1 dose group: 0.25×10\^6 CAR-T live cells /kg body weight~Group A (initial dose) : 0.5×10\^6 CAR-T live cells /kg body weight~Group B: 1.0×10\^6 CAR-T live cells /kg body weight~Group C: 1.5×10\^6 CAR-T live cells /kg body weight"

Sponsors
All Listed Sponsors
lead

Juventas Cell Therapy Ltd.

INDUSTRY